

## Special Issue

# Factors Associated with COVID-19 Vaccination Intentions

### Message from the Guest Editor

Vaccination is one of the most effective methods available to reduce the spread of SARS-CoV-2. Mass vaccination against COVID-19 will help to control the pandemic, and adequate uptake is essential to reach herd immunity. Many countries and regions have mitigated the spread of COVID-19 by prompting and encouraging vaccinations. However, COVID-19 vaccine hesitancy is unfortunately still an issue in some places. According to recent studies, lack of intention to receive a vaccination is associated with low educational attainment, low COVID-19 knowledge levels, and low income. Understanding the factors that affect COVID-19 vaccination intention is crucial to the establishment of broad vaccination programmes. This Special Issue aims to encourage more research studies on factors associated with COVID-19 vaccination intention and prompt the understanding of individuals' attitudes. Qualitative and quantitative research should focus on this area in order to help policy makers increase vaccination uptake and ultimately achieve herd immunity.

### Guest Editor

Dr. Petros Galanis

Clinical Epidemiology Laboratory, Faculty of Nursing, National and Kapodistrian University of Athens, 11527 Athens, Greece

### Deadline for manuscript submissions

closed (31 May 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/124398](https://mdpi.com/si/124398)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).